头盔无创通气治疗慢性阻塞性肺疾病急性加重所致呼吸衰竭
该单中心随机对照研究纳入26例慢性阻塞性肺疾病急性加重(AECOPD)合并呼吸衰竭的急诊重症监护病房(EICU)和呼吸重症监护病房(RICU)患者,随机分为头盔组和面罩组各13例,比较无创通气(NIV)的疗效与耐受性。结果显示头盔组NIV结束时氧合指数(PaO2/FiO2)较NIV即刻的增加值显著高于面罩组(75.1±73.2 mmHg vs. 7.7±86.0 mmHg,P<0.05),各时间点呼吸频率(RR)更低,4小时和NIV结束时耐受评分更高,总并发症(3例 vs. 8例)和鼻部皮肤损伤(0例 vs. 4例)更少。两组pH值、动脉血二氧化碳分压(PaCO2)、心率(HR)改善无显著差异,气管插管率和院内病死率无显著差异,30天累积生存率无统计学显著差异(Log-Rank检验:χ2=1.278,P=0.258)。作者认为头盔NIV对AECOPD合并呼吸衰竭患者舒适度更好,改善氧合和缓解呼吸困难效果更优,二氧化碳潴留改善不劣于传统面罩NIV。
要点
- 头盔组NIV结束时PaO2/FiO2较NIV即刻的增加值显著高于面罩组(75.1±73.2 mmHg vs. 7.7±86.0 mmHg,P<0.05)。
- 头盔组NIV后1小时、4小时和结束时RR均显著低于面罩组(1小时:17.5±4.1 vs. 23.1±6.3次/min;4小时:16.2±2.5 vs. 20.0±5.5次/min;结束时:15.5±2.5 vs. 21.2±5.9次/min,均P<0.05)。
- 头盔组4小时和NIV结束时耐受评分显著高于面罩组(4小时:3.9±0.3 vs. 3.3±0.9;结束时:3.8±0.6 vs. 2.9±0.9,均P<0.05)。
- 头盔组总并发症(3例 vs. 8例)和鼻部皮肤损伤(0例 vs. 4例)均显著少于面罩组(均P<0.05)。
- 两组气管插管率、院内病死率和30天累积生存率无显著差异(均P>0.05;Log-Rank检验:χ2=1.278,P=0.258)。
适用人群与场景
- 2018年1月1日至2019年5月31日郑州大学第一附属医院EICU和RICU收治的AECOPD合并呼吸衰竭患者82例,排除氧合指数(PaO2/FiO2)>200 mmHg、已气管插管或有创通气、急性心肌梗死、2周内严重创伤、分泌物过多、排痰障碍或拒绝参与者,最终26例纳入分析。
研究设计与关键结果
- 单中心随机对照研究,最终纳入26例AECOPD合并呼吸衰竭患者,随机分为头盔组和面罩组各13例,分别使用头盔或面罩进行NIV。
- 头盔组NIV结束时PaO2/FiO2较NIV即刻的增加值显著高于面罩组(75.1±73.2 mmHg vs. 7.7±86.0 mmHg,P<0.05);两组NIV后PaO2/FiO2均较NIV即刻显著升高,组间无显著差异。
- 头盔组NIV后1小时、4小时和结束时RR均显著低于面罩组(1小时:17.5±4.1 vs. 23.1±6.3次/min;4小时:16.2±2.5 vs. 20.0±5.5次/min;结束时:15.5±2.5 vs. 21.2±5.9次/min,均P<0.05)。
- 头盔组4小时和NIV结束时耐受评分显著高于面罩组(4小时:3.9±0.3 vs. 3.3±0.9;结束时:3.8±0.6 vs. 2.9±0.9,均P<0.05)。
- 头盔组总并发症(3例 vs. 8例)和鼻部皮肤损伤(0例 vs. 4例)均显著少于面罩组(均P<0.05)。
- 两组pH值、PaCO2和HR改善无显著差异;头盔组气管插管2例(其中1例死亡),面罩组气管插管5例(其中3例死亡),两组气管插管率和院内病死率无显著差异(均P>0.05)。
- 30天累积生存率头盔组低于面罩组,但差异无统计学意义(Log-Rank检验:χ2=1.278,P=0.258)。
证据类型、等级与局限
- 研究类型:单中心随机对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对AECOPD合并呼吸衰竭患者,头盔NIV舒适度更好,改善氧合和缓解呼吸困难效果更优,二氧化碳潴留改善不劣于传统面罩NIV。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effect and tolerance of non-invasive ventilation (NIV) with helmet in patients with respiratory failure caused by acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the effect on improving blood gas, alleviating dyspnea and the occurrence of complications.
METHODS: Patients with AECOPD and respiratory failure admitted to emergency intensive care unit (EICU) and respiratory intensive care unit (RICU) of the First Affiliated Hospital of Zhengzhou University from January 1st, 2018 to May 31st, 2019 were enrolled. After obtaining the informed consent of the patients or their authorized family members, the patients were divided into two groups: the helmet group and the facial mask group by random number table. NIV was carried out by using helmet or facial mask, respectively. During the course of NIV (immediately, 1 hour, 4 hours and at the end of NIV), the tolerance score, blood gas analysis, heart rate (HR), respiratory rate (RR) of patients were monitored, and the incidence of tracheal intubation, in-hospital mortality and complications were observed. Kaplan-Meier survival curve was plotted to analyze the 30-day cumulative survival of the two groups.
RESULTS: A total of 82 patients with AECOPD and respiratory failure were included during the study period. After excluding patients with the oxygenation index (PaO2/FiO2) > 200 mmHg (1 mmHg = 0.133 kPa), with tracheal intubation or invasive ventilation, suffering from acute myocardial infarction, severe trauma within 2 weeks, excessive secretion, sputum discharge disorder or refusal to participate in the study, 26 patients were finally enrolled in the analysis, randomly assigned to the helmet group and the facial mask group, with 13 patients in each group. The PaO2/FiO2 after NIV of patients in both groups was increased significantly as compared with that immediately after NIV, without significant difference between the two groups, but the increase in PaO2/FiO2 at the end of NIV compared with immediately after NIV in the helmet group was significantly higher than that in the facial mask group (mmHg: 75.1±73.2 vs. 7.7±86.0, P < 0.05). RR at each time point after NIV in the two groups was lower than that immediately after NIV, especially in the helmet group. There were significant differences between the helmet group and facial mask group at 1 hour, 4 hours, and the end of NIV (times/min: 17.5±4.1 vs. 23.1±6.3 at 1 hour, 16.2±2.5 vs. 20.0±5.5 at 4 hours, 15.5±2.5 vs. 21.2±5.9 at the end of NIV, all P < 0.05). The NIV tolerance score of the helmet group at 4 hours and the end was significantly higher than that of the facial mask group (4 hours: 3.9±0.3 vs. 3.3±0.9, at the end of NIV: 3.8±0.6 vs. 2.9±0.9, both P < 0.05). There was no significant difference in the improvement of pH value, arterial partial pressure of carbon dioxide (PaCO2), or HR between helmet group and facial mask group. The total number of complications (cases: 3 vs. 8) and the nasal skin lesions (cases: 0 vs. 4) in the helmet group were significantly less than those in the facial mask group (both P < 0.05). Only 2 patients in the helmet group received endotracheal intubation, and 1 of them died; 5 patients in the facial mask group received endotracheal intubation, and 3 of them died; there was no significant difference between the two groups (both P > 0.05). The Kaplan-Meier survival curve analysis showed that the cumulative survival rate of 30 days in the helmet group was lower than that in the facial mask group, but the difference was not statistically significant (Log-Rank test: χ2 = 1.278, P = 0.258).
CONCLUSIONS: NIV with helmet has better comfort for patients with AECOPD combined with respiratory failure, and better effect on improving oxygenation and relieving dyspnea, and its effect on carbon dioxide emissions is not inferior to that of traditional mask NIV.
参考来源
- Liu Q, Lu H, Shan M, et al. [Non-invasive ventilation with helmet in patients with respiratory failure caused by acute exacerbation of chronic obstructive pulmonary disease]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32148225. doi:10.3760/cma.j.cn121430-20191219-00003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。